Cover Image
市場調查報告書

痛覺過敏症:開發平台分析

Hyperalgesia - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 293882
出版日期 內容資訊 英文 36 Pages
訂單完成後即時交付
價格
Back to Top
痛覺過敏症:開發平台分析 Hyperalgesia - Pipeline Review, H2 2016
出版日期: 2016年07月13日 內容資訊: 英文 36 Pages
簡介

痛覺過敏症是對疼痛的反應增大。致病因子包含了長期使用Opioids(類鴉片物質)、發炎、侵害受體的損傷、末梢神經的損傷及精神的疾病等。治療方法有使用抗憂鬱症藥及非類固醇系抗發炎藥。

本報告提供痛覺過敏症治療藥的開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,及藥物簡介等相關的系統性資訊。

目錄

簡介

痛覺過敏症概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

開發中的治療藥:大學/研究機關別

開發中產品概要

  • 初期階段的產品

開發中的產品:各企業

開發中的產品:大學/研究機關別

開發治療藥的企業

  • Cara Therapeutics, Inc.
  • 鹽野義製藥

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • AX-007
  • BAM-822
  • CR-701
  • GERPOOI
  • ketoprofen
  • LASSBio-873
  • Recombinant Protein to Activate IL-4 and IL-10 Receptors for Osteoarthritis and CNS
  • Small Molecule to Antagonize P2X3 Receptor for Hyperalgesia

最新開發平台趨勢

暫停的計劃

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8224IDB

Summary

Global Markets Direct's, 'Hyperalgesia - Pipeline Review, H2 2016', provides an overview of the Hyperalgesia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hyperalgesia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hyperalgesia and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Hyperalgesia
  • The report reviews pipeline therapeutics for Hyperalgesia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Hyperalgesia therapeutics and enlists all their major and minor projects
  • The report assesses Hyperalgesia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Hyperalgesia

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Hyperalgesia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Hyperalgesia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hyperalgesia Overview
  • Therapeutics Development
    • Pipeline Products for Hyperalgesia - Overview
    • Pipeline Products for Hyperalgesia - Comparative Analysis
  • Hyperalgesia - Therapeutics under Development by Companies
  • Hyperalgesia - Therapeutics under Investigation by Universities/Institutes
  • Hyperalgesia - Pipeline Products Glance
    • Early Stage Products
  • Hyperalgesia - Products under Development by Companies
  • Hyperalgesia - Products under Investigation by Universities/Institutes
  • Hyperalgesia - Companies Involved in Therapeutics Development
    • Boehringer Ingelheim GmbH
    • Cara Therapeutics, Inc.
    • Shionogi & Co., Ltd.
  • Hyperalgesia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AX-007 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BAM-822 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BI-113823 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CR-701 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GERP-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ketoprofen - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LASSBio-873 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize P2X3 Receptor for Hyperalgesia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Hyperalgesia - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Hyperalgesia, H2 2016
  • Number of Products under Development for Hyperalgesia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Hyperalgesia - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Hyperalgesia - Pipeline by Cara Therapeutics, Inc., H2 2016
  • Hyperalgesia - Pipeline by Shionogi & Co., Ltd., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Hyperalgesia - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Hyperalgesia - Comparative Analysis, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top